Antitumor effect of a generation 4 polyamidoamine dendrimer/cyclooxygenase- 2 antisense oligodeoxynucleotide complex on breast cancer in vitro and in vivo

Cancer Biotherapy and Radiopharmaceuticals

Volumn 27, Issue 1, 2012, Pages 77-87

  Xin, Guohong ^a   Zhao, Xinhan ^a   Duan, Xinlei ^a   Ning, Qian ^a   Meng, Min ^a   Meng, Du ^a   Liu, Lifeng ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

breast cancer; COX 2; G4PAMAM; G4PAMAM COX 2ASODN; gene therapy

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; CYCLOOXYGENASE 2; DENDRIMER; GENERATION 4 POLYAMIDOAMINE DENDRIMER CYCLOOXYGENASE 2 ANTISENSE OLIGODEOXYNUCLEOTIDE COMPLEX; MESSENGER RNA; POLYAMIDOAMINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CAPILLARY DENSITY; CELL CYCLE ARREST; CELL INVASION; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GENE THERAPY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; APOPTOSIS; BREAST NEOPLASMS; CELL CYCLE; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CYCLOOXYGENASE 2; DENDRIMERS; FEMALE; FLOW CYTOMETRY; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; NYLONS; OLIGODEOXYRIBONUCLEOTIDES; OLIGONUCLEOTIDES, ANTISENSE; TRANSFECTION;

EID: 84863174874     PISSN: 10849785     EISSN: 15578852     Source Type: Journal    
DOI: 10.1089/cbr.2011.1028     Document Type: Article

References (45)

1. Smith WL, Garavito RM, DeWitt DL. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem 1996;271:33157.
2. von Rahden BH, Stein HJ, Puhringer F, et al. Coexpression of cyclooxygenases (COX-1, COX-2) and vascular endothelial growth factors (VEGF-A, VEGF-C) in esophageal adenocarcinoma. Cancer Res 2005;65:5038.
3. Sheehan KM, Sheahan K, O'Donoghue DP, et al. The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA 1999;282:1254.
4. Cha YI, Solnica-Krezel L, DuBois RN. Fishing for prostanoids: Deciphering the developmental functions of cyclooxygenasederived prostaglandins. Dev Biol 2006;289:263.
5. Tsujii M, Kawano S, Tsuji S, et al. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998; 93:705.
6. Basu GD, Liang WS, Stephan DA, et al. A novel role for cyclooxygenase-2 in regulating vascular channel formation by human breast cancer cells. Breast Cancer Res 2006;8:R69.
7. Zhang XH, Huang DP, Guo GL, et al. Coexpression of VEGF-C and COX-2 and its association with lymphangiogenesis in human breast cancer. BMC Cancer 2008;8:4.
8. Gee J, Lee IL, Grossman HB, Sabichi AL. Forced COX-2 expression induces PGE2 and invasion in immortalized urothelial cells. Urol Oncol 2008;26:641.
9. Hiraga T, Myoui A, Choi ME, et al. Stimulation of cyclooxygenase- 2 expression by bone-derived transforming growth factor-beta enhances bone metastases in breast cancer. Cancer Res 2006;66:2067.
10. Choi EM, Kim SR, Lee EJ, Han JA. Cyclooxygenase-2 functionally inactivates p53 through a physical interaction with p53. Biochim Biophys Acta 2009;1793:1354.
11. Al-Salihi MA, Ulmer SC, Doan T, et al. Cyclooxygenase- 2 transactivates the epidermal growth factor receptor through specific E-prostanoid receptors and tumor necrosis factor-alpha converting enzyme. Cell Signal 2007;19:1956.
12. Singh B, Cook KR, Vincent L, et al. Cyclooxygenase-2 induces genomic instability, BCL2 expression, doxorubicin resistance, and altered cancer-initiating cell phenotype in MCF7 breast cancer cells. J Surg Res 2008;147:240.
13. Singh B, Vincent L, Berry JA, et al. Cyclooxygenase-2 expression induces genomic instability in MCF10A breast epithelial cells. J Surg Res 2007;140:220.
14. Barnes NL, Warnberg F, Farnie G, et al. Cyclooxygenase-2 inhibition: Effects on tumour growth, cell cycling and lymphangiogenesis in a xenograft model of breast cancer. Br J Cancer 2007;96:575.
15. Chen B, Su B, Chen S. A COX-2 inhibitor nimesulide analog selectively induces apoptosis in Her2 overexpressing breast cancer cells via cytochrome C dependent mechanisms. Biochem Pharmacol 2009;77:1787.
16. Qin J, Yuan J, Li L, et al. In vitro and in vivo inhibitory effect evaluation of cyclooxygenase-2 inhibitors, antisense cyclooxygenase-2 cDNA, and their combination on the growth of human bladder cancer cells. Biomed Pharmacother 2009;63:241.
17. Larkins TL, Nowell M, Singh S, Sanford GL. Inhibition of cyclooxygenase-2 decreases breast cancer cell motility, invasion and matrix metalloproteinase expression. BMC Cancer 2006;10:181.
18. Sü leyman, H, Demircan B, Karagöz Y. Anti-inflammatory and side effects of cyclooxygenase inhibitors. Pharmacol Rep 2007;59:247.
19. Putnam DA. Antisense strategies and therapeutic applications. Am J Health Syst Pharm 1996;53:151.
20. Choi JS, Nam K, Park JY, et al. Enhanced transfection efficiency of PAMAM dendrimer by surface modification with L-arginine. J Control Release 2004;99:445.
21. Maiti PK, Cagin T, Wang GF, Goddard WA III. Structure of PAMAM dendrimers: Generations 1 through 11. Macromolecules 2004;37:6236.
22. Kukowska-Latallo JF, Bielinska AU, Johnson J, et al. Efficient transfer of genetic material into mammalian cells using Starburst polyamidoamine dendrimers. Proc Natl Acad Sci USA 1996;93:4897.
23. Bielinska A, Kukowska-Latallo JF, Johnson J, et al. Regulation of in vitro gene expression using antisense oligonucleotides or antisense expression plasmids transfected using starburst PAMAM dendrimers. Nucleic Acids Res 1996;24:2176.
24. Sonawane ND, Szoka FC Jr, Verkman AS. Chloride accumulation and swelling in endosomes enhances DNA transfer by polyamine-DNA polyplexes. J Biol Chem 2003;278:44826.
25. Kubasiak LA, Tomalia DA. Cationic Dendrimers as Gene Transfection Vectors: Dendri-Poly(amidoamines) and Dendri-Poly(propylenimines). Boca Raton, Fla: CRC Press, 2004, chapter 9: p 133.
26. Braun CS, Vetro JA, Tomalia DA, et al. Structure/function relationships of polyamidoamine/DNA dendrimers as gene delivery vehicles. J Pharm Sci 2005;94:423.
27. Abdelhady HG, Allen S, Davies MC, et al. Direct real-time molecular scale visualisation of the degradation of condensed DNA complexes exposed to DNase I. Nucleic Acids Res 2003;31:4001.
28. Mislick KA, Baldeschwieler JD. Evidence for the role of proteoglycans in cation-mediated gene transfer. Proc Natl Acad Sci U S A 1996;93:12349.
29. Mounkes LC, Zhong W, Cipres-Palacin G, et al. Proteoglycans mediate cationic liposome-DNA complex-based gene delivery in vitro and in vivo. J Biol Chem 1998;273:26164.
30. Jevprasesphant R, Penny J, Jalal R, et al. The influence of surface modification on the cytotoxicity of PAMAM dendrimers. Int J Pharm 2003;252:263.
31. Fischer D, Li Y, Ahlemeyer B, et al. In vitro cytotoxicity testing of polycations: Influence of polymer structure on cell viability and hemolysis. Biomaterials 2003;24:1121.
32. Morgan DM, Larvin VL, Pearson JD. Biochemical characterization of polycation-induced cytotoxicity to human vascular endothelial cells. J Cell Sci 1989;94:553.
33. Kono K, Akiyama H, Takahashi T, et al. Transfection activity of polyamidoamine dendrimers having hydrophobic amino acid residues in the periphery. Bioconjug Chem 2005;16:208.
34. Shakhbazaua A, Isayenka I, Kartel N, et al. Transfection efficiencies of PAMAM dendrimers correlate inversely with their hydrophobicity. Int J Pharm 2010;383:228.
35. Pavan GM, Albertazzi L, Danani A. Ability to adapt: Different generations of PAMAM dendrimers show different behaviors in binding siRNA. J Phys Chem B 2010; 114:2667.
36. Li H, Bian C, Liao L, et al. miR-17-5p promotes human breast cancer cell migration and invasion through suppression of HBP1. Breast Cancer Res Treat 2011;126:565.
37. Ekici S, Cerwinka WH, Duncan R, et al. Comparison of the prognostic potential of hyaluronic acid, hyaluronidase (HYAL-1), CD44v6 and microvessel density for prostate cancer. Int J Cancer 2004;112:121.
38. Rejman J, Bragonzi A, Conese M. Role of clathrin- and caveolae-mediated endocytosis in gene transfer mediated by lipo- and polyplexes. Mol Ther 2005;12:468.
39. Boussif O, Lezoualc'h F, Zanta MA, et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: Polyethylenimine. Proc Natl Acad Sci U S A 1995;92:7297.
40. Denkert C, Fü rstenberg A, Daniel PT, et al. Induction of G0/ G1 cell cycle arrest in ovarian carcinoma cells by the anti-inflammatory drug NS-398, but not by COX-2-specific RNA interference. Oncogene 2003;22:8653.
41. Walder RY, Walder JA. Role of RNase H in hybrid-arrested translation by antisense oligonucleotides. Proc Natl Acad Sci U S A 1988;85:5011.
42. Baker BF, Lot SS, Condon TP, et al. 2'-O-(2-Methoxy)ethylmodified anti-intercellular adhesion molecule 1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation initiation complex in human umbilical vein endothelial cells. J Biol Chem 1997;272:11994.
43. Dias N, Dheur S, Nielsen PE, et al. Antisense PNA tridecamers targeted to the coding region of Ha-ras mRNA arrest polypeptide chain elongation. J Mol Biol 1999;294:403.
44. Dandekar DS, Lokeshwar BL. Inhibition of cyclooxygenase (COX)-2 expression by Tet-inducible COX-2 antisense cDNA in hormone-refractory prostate cancer significantly slows tumor growth and improves efficacy of chemotherapeutic drugs. Clin Cancer Res 2004;10:8037.
45. Fu YG, Sung JJ, Wu KC, et al. Inhibition of gastric cancerassociated angiogenesis by antisense COX-2 transfectants. Cancer Lett 2005;224:243.